145 related articles for article (PubMed ID: 21051931)
1. Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia.
Irving L; Mainou-Fowler T; Parker A; Ibbotson RE; Oscier DG; Strathdee G
Epigenetics; 2011 Mar; 6(3):300-6. PubMed ID: 21051931
[TBL] [Abstract][Full Text] [Related]
2. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
Li FJ; Ding S; Pan J; Shakhmatov MA; Kashentseva E; Wu J; Li Y; Soong SJ; Chiorazzi N; Davis RS
Blood; 2008 Jul; 112(1):179-87. PubMed ID: 18314442
[TBL] [Abstract][Full Text] [Related]
3. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
Rassenti LZ; Jain S; Keating MJ; Wierda WG; Grever MR; Byrd JC; Kay NE; Brown JR; Gribben JG; Neuberg DS; He F; Greaves AW; Rai KR; Kipps TJ
Blood; 2008 Sep; 112(5):1923-30. PubMed ID: 18577710
[TBL] [Abstract][Full Text] [Related]
4. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia.
Buhl AM; Jurlander J; Geisler CH; Pedersen LB; Andersen MK; Josefsson P; Petersen JH; Leffers H
Eur J Haematol; 2006 Jun; 76(6):455-64. PubMed ID: 16529606
[TBL] [Abstract][Full Text] [Related]
5. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.
Morilla A; Gonzalez de Castro D; Del Giudice I; Osuji N; Else M; Morilla R; Brito Babapulle V; Rudenko H; Matutes E; Dearden C; Catovsky D; Morgan GJ
Leuk Lymphoma; 2008 Nov; 49(11):2108-15. PubMed ID: 19021053
[TBL] [Abstract][Full Text] [Related]
6. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia.
Stamatopoulos B; Meuleman N; Haibe-Kains B; Duvillier H; Massy M; Martiat P; Bron D; Lagneaux L
Clin Chem; 2007 Oct; 53(10):1757-66. PubMed ID: 17702857
[TBL] [Abstract][Full Text] [Related]
7. Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia.
Visentin A; Facco M; Frezzato F; Castelli M; Trimarco V; Martini V; Gattazzo C; Severin F; Chiodin G; Martines A; Bonaldi L; Gianesello I; Pagnin E; Boscaro E; Piazza F; Zambello R; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):612-20.e1-5. PubMed ID: 26233718
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.
Wojdacz TK; Amarasinghe HE; Kadalayil L; Beattie A; Forster J; Blakemore SJ; Parker H; Bryant D; Larrayoz M; Clifford R; Robbe P; Davis ZA; Else M; Howard DR; Stamatopoulos B; Steele AJ; Rosenquist R; Collins A; Pettitt AR; Hillmen P; Plass C; Schuh A; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Oakes CC; Strefford JC
Blood Adv; 2019 Aug; 3(16):2474-2481. PubMed ID: 31434681
[TBL] [Abstract][Full Text] [Related]
9. Biological prognostic markers in chronic lymphocytic leukemia.
Vroblová V; Smolej L; Vrbacký F; Jankovicová K; Hrudková M; Malý J; Krejsek J
Acta Medica (Hradec Kralove); 2009; 52(1):3-8. PubMed ID: 19754000
[TBL] [Abstract][Full Text] [Related]
10. Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia.
Abo Elwafa R; Abd Elrahman A; Ghallab O
Clin Transl Oncol; 2021 Jan; 23(1):92-99. PubMed ID: 32468342
[TBL] [Abstract][Full Text] [Related]
11. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
Raponi S; Ilari C; Della Starza I; Cappelli LV; Cafforio L; Piciocchi A; Arena V; Mariglia P; Mauro FR; Gentile M; Cutrona G; Moia R; Favini C; Morabito F; Rossi D; Gaidano G; Guarini A; Del Giudice I; Foà R
Br J Haematol; 2020 Jun; 189(5):853-859. PubMed ID: 32064595
[TBL] [Abstract][Full Text] [Related]
12. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
[TBL] [Abstract][Full Text] [Related]
13. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
[TBL] [Abstract][Full Text] [Related]
14. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.
Hamblin TJ; Orchard JA; Ibbotson RE; Davis Z; Thomas PW; Stevenson FK; Oscier DG
Blood; 2002 Feb; 99(3):1023-9. PubMed ID: 11807008
[TBL] [Abstract][Full Text] [Related]
15. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.
Jelinek DF; Tschumper RC; Geyer SM; Bone ND; Dewald GW; Hanson CA; Stenson MJ; Witzig TE; Tefferi A; Kay NE
Br J Haematol; 2001 Dec; 115(4):854-61. PubMed ID: 11843819
[TBL] [Abstract][Full Text] [Related]
16. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
17. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
[TBL] [Abstract][Full Text] [Related]
18. MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Ito M; Iida S; Inagaki H; Tsuboi K; Komatsu H; Yamaguchi M; Nakamura N; Suzuki R; Seto M; Nakamura S; Morishima Y; Ueda R
Jpn J Cancer Res; 2002 Jun; 93(6):685-94. PubMed ID: 12079517
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig V(H) genes.
Cochran DA; Evans CA; Blinco D; Burthem J; Stevenson FK; Gaskell SJ; Whetton AD
Mol Cell Proteomics; 2003 Dec; 2(12):1331-41. PubMed ID: 14557598
[TBL] [Abstract][Full Text] [Related]
20. Large-scale analysis of DNA methylation in chronic lymphocytic leukemia.
Rahmatpanah FB; Carstens S; Hooshmand SI; Welsh EC; Sjahputera O; Taylor KH; Bennett LB; Shi H; Davis JW; Arthur GL; Shanafelt TD; Kay NE; Wooldridge JE; Caldwell CW
Epigenomics; 2009 Oct; 1(1):39-61. PubMed ID: 20495622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
